Cision PR Newswire
Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
News provided byCorbus Pharmaceuticals
Sep 19, 2023, 8:00 AM ET
NORWOOD, Mass., Sept. 19, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the pre-clinical data on its CRB-701 Nectin-4 anti-drug-conjugate (ADC) will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, to be held in Boston, MA October 11-15, 2023.
Development of CRB-701 (SYS6002): A novel site-specific, Nectin-4 targeting ADC
Zhaopeng Sun, Mo Dan, Lu Lv, Can Yuan, Congcong Niu, Yang Zhang, Mingyue Shen,
Saturday, October 14 from 12:30-4 P.M.
Corbus Pharmaceuticals Holdings, Inc. (the "Company" or "Corbus") is a precision oncology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus' internal development pipeline includes CRB-701, a next generation antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Chief Financial Officer
LifeSci Advisors, LLC
View original content to download multimedia:https://www.prnewswire.com/news-releases/corbus-pharmaceuticals-to-present-pre-clinical-data-characterizing-its-crb-701-nectin-4-adc-at-the-at-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-301931639.html
SOURCE Corbus Pharmaceuticals
NOTE: This content is not written by or endorsed by "KSWB", its advertisers, or Nexstar Media Inc.